ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.690
0.00 (0.00%)
At close: Apr 23, 2025, 4:00 PM
2.680
-0.010 (-0.37%)
After-hours: Apr 23, 2025, 7:50 PM EDT
ImmunityBio Revenue
In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth. ImmunityBio had revenue of $7.55M in the quarter ending December 31, 2024, with 5,333.09% growth.
Revenue (ttm)
$14.75M
Revenue Growth
+2,270.58%
P/S Ratio
127.22
Revenue / Employee
$21,684
Employees
680
Market Cap
2.37B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
IBRX News
- 2 days ago - ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - Business Wire
- 8 days ago - ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire
- 15 days ago - ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire
- 16 days ago - ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire
- 20 days ago - ImmunityBio: Taking Care Of Business - Seeking Alpha
- 4 weeks ago - ImmunityBio to Host Investor Day - Business Wire
- 5 weeks ago - ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching - Business Wire
- 6 weeks ago - ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha